Industry News

Novo Nordisk has launched legal action against US telehealth company Hims & Hers, accusing it of unlawfully marketing unapproved and potentially unsafe compounded versions of its bestselling GLP-1 medicines Wegovy® and Ozempic®.

Lupin Limited has reached a settlement and licensing agreement with Astellas Pharma and its group companies, bringing an end to the long-running patent infringement litigation related to the overactive bladder drug Mirabegron (marketed by Astellas as Myrbetriq).

Lupin said the agreement was signed by the company and its wholly owned US subsidiary, Lupin Pharmaceuticals, Inc., with Astellas Pharma, Inc., Astellas Ireland Co., Ltd., and Astellas Pharma Global Development, Inc.

Zydus Lifesciences has achieved a significant regulatory milestone as the U.S. Food and Drug Administration (USFDA) granted Orphan Drug Designation (ODD) to its novel molecule Desidustat for the treatment of Sickle Cell Disease (SCD). The designation highlights the growing recognition of the urgent need for new and effective therapies in this rare and challenging condition.

Emcure Pharmaceuticals Ltd. announced robust financial results for the third quarter of the 2025-26 fiscal year, marking significant growth across both domestic and international businesses. The company reported a notable rise in profitability and topline performance, underpinned by diversified portfolio strength and strategic initiatives.